Semax 10mg – Synthetic Research Peptide
Semax is a synthetic heptapeptide first synthesized by Russian research institutions in the 1980s, engineered as an analog of the endogenous ACTH (4-10) fragment. Its sequence, Met-Glu-His-Phe-Pro-Gly-Pro, reflects targeted structural modifications intended to improve resistance to enzymatic breakdown relative to the native ACTH fragment it’s derived from. A substantial body of biochemical and cellular neurobiology literature has examined this compound.
Each vial ships with 10mg of lyophilized Semax sealed in a 3mL glass vial, backed by Phantom Peptides’ internal verification standard: independent third-party lab analysis.
Product Specifications
- Compound: Semax
- Class: Synthetic heptapeptide / ACTH (4-10) analog
- Sequence: Met-Glu-His-Phe-Pro-Gly-Pro
- Molecular Weight: ~813 Da
- Form: Lyophilized powder
- Vial Size: 10mg / 3mL glass vial
- Purity: 99%+, confirmed via HPLC and mass spec (COAs available)
Research Background
The existing literature on Semax spans a handful of distinct research threads:
- Neuronal signaling research: how the peptide interacts with signaling pathways in cultured neuronal cell models
- BDNF/neurotrophin pathway studies: cell culture work looking at downstream effects on brain derived neurotrophic factor signaling
- Melanocortin receptor pharmacology: binding profile studies on ACTH fragment derived peptides at melanocortin receptors
- Structure stability research: side by side comparisons of Semax against native ACTH (4-10), focused on how the sequence modification changes half-life and degradation resistance
- Oxidative stress models: cellular response studies in neuronal models exposed to oxidative conditions
- Comparative peptide research: Semax examined alongside structurally related research peptides in cell based studies
Development traces back to the Institute of Molecular Genetics at the Russian Academy of Sciences, with the deepest body of published work coming out of the Myasoedov lab and affiliated Russian peptide research groups. For primary sources, PubMed (pubmed.ncbi.nlm.nih.gov) and NIH’s PMC database (pmc.ncbi.nlm.nih.gov) index the peer reviewed literature on Semax and ACTH derived peptide research.
